PHIO · Phio Pharmaceuticals Corp.
$1.13
+0.01 (+0.89%)
At close · Aug 28
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has limited cash resources, has incurred recurring operating losses and negative cash flows from its operations since its inception and has not yet recognized any product revenues. These factors have previously raised doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$13.13M
Shares
11.62M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
-100%
FY2020
Net Income
-$8.7M
-21.7%
FY2025
Operating Margin
-42795.24%
-37459pp
FY2019
Diluted EPS
-$9.08
+80.6%
FY2024
Operating Cash Flow
-$7.98M
-12.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 | FY2006 | FY2005 | FY2004 | FY2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | $0 | $21K | $138K | $15K | $19K | $34K | — | $399K | $97K | — | — | — | — | — | — | — | — | — | |
| — | — | $231K | -$8000 | — | — | — | — | — | — | — | — | — | $24K | -$30K | — | — | — | — | — | — | — | — | — | |
| $8.53M | $4.62M | $3.64M | $6.33M | $7.01M | $8.89M | $3.72M | $4.3M | $4.33M | $5.37M | $5.42M | $6.93M | $5.68M | $17.65M | $10.45M | $6.62M | — | — | — | — | — | — | — | — | |
| $4.94M | $4.6M | $3.74M | $4.37M | $4.45M | $4.63M | $5.08M | $4.71M | $3.18M | $4.01M | $3.62M | $3.35M | $3.22M | $3.7M | $2.62M | $6.15M | — | — | — | — | — | — | — | — | |
| $5000 | $3000 | $2000 | $56K | $71K | $75K | $72K | $67K | $81K | $70K | $53K | $77K | $87K | $99K | $147K | $163K | — | — | — | — | — | — | — | — | |
| $13.47M | $9.22M | $7.39M | $10.82M | $11.46M | $13.51M | $8.79M | $9.01M | $7.5M | $14.08M | $9.03M | $10.27M | $8.9M | $21.35M | $13.07M | — | — | — | — | — | — | — | — | — | |
| -$13.47M | -$9.22M | -$7.39M | -$10.82M | -$11.46M | -$13.51M | -$8.79M | -$8.99M | -$7.36M | -$14.06M | -$9.02M | -$10.24M | -$8.83M | -$20.95M | -$12.98M | -$12.77M | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | -42795.24% | -5336.23% | -93746.67% | -47447.37% | -30108.82% | — | -5250.38% | -13376.29% | — | — | — | — | — | — | — | — | — | |
| -$13.47M | -$9.22M | -$7.39M | -$10.77M | -$11.39M | -$13.44M | -$8.72M | -$8.92M | -$7.28M | -$13.99M | -$8.96M | -$10.16M | -$8.74M | -$20.85M | -$12.83M | -$12.61M | — | — | — | — | — | — | — | — | |
| $27K | $2000 | $6000 | -$2000 | -$18K | $224K | -$1000 | $79K | $4000 | -$11K | $21K | $14K | $26K | — | $125K | $2.55M | — | — | — | — | — | — | — | — | |
| — | — | — | — | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$14.07M | -$8.99M | -$10.22M | -$8.8M | -$20.93M | -$12.88M | -$10.22M | — | — | — | — | — | — | — | — | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$1.62M | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | |
| -$12.9M | -$8.7M | -$7.15M | -$10.83M | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$12.45M | -$8.99M | -$10.22M | -$8.8M | -$20.93M | -$12.88M | -$2.54M | -$11.99M | -$18.39M | -$14.37M | -$10.99M | -$2.41M | -$2.21M | -$3.27M | -$89K | |
| — | — | — | — | — | — | — | -42419.05% | -5333.33% | -83013.33% | -47336.84% | -30067.65% | — | -5244.36% | -13278.35% | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | -$12.45M | -$11.07M | -$10.43M | -$12.93M | -$29.54M | -$25.7M | -$10.22M | — | — | — | — | — | — | — | — | |
| USD/shares | -$1.29 | -$1.45 | -$9.08 | -$46.76 | -$90.90 | -$111.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$5.85 | — | -$9.08 | -$46.76 | -$90.90 | -$111.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | 5.98M | 787.47K | 231.51K | 126.29K | 118.8K | 42.48K | 4266.75 | 1185.9722 | 380.0933 | 113.5704 | 836.7646 | 2754.6978 | 1727.9384 | 769.9978 | 6116.9045 | — | — | — | — | — | — | — | — |
| shares | — | — | 787.47K | 231.51K | 126.29K | 118.8K | 42.48K | 4266.75 | 1185.9722 | 380.0933 | 113.5704 | 836.7646 | 2754.6978 | 1727.9384 | 769.9978 | 6116.9045 | — | — | — | — | — | — | — | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.77×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.89×
Peer medians compare against the 210 similar-size Biotechnology companies (of 508 listed).